Management of Nausea and Vomiting Following First-Line Zolbetuximab + Chemotherapy

Nausea and vomiting emerged as the most frequent treatment-related adverse events among patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with zolbetuximab plus chemotherapy. In this MEDtalk, Dr. Kohei Shitara elaborates the management strategies for these side effects.